Engineered immune cells take on tough lymphoma

NCT ID NCT04083495

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times

Summary

This study tests a new treatment for people with a rare type of blood cancer (peripheral T-cell lymphoma) that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to recognize and attack cancer cells, and giving them back after a short course of chemotherapy. The goal is to see if this approach can control the cancer and improve survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lineberger Comprehensive Cancer Center at University of North Carolina

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wake Forest Baptist Medical Center

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.